U.S. markets closed

Viela Bio, Inc. (VIE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.74+0.67 (+2.09%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close32.07
Open32.41
Bid32.48 x 800
Ask32.72 x 900
Day's Range31.25 - 32.75
52 Week Range19.60 - 70.66
Volume89,244
Avg. Volume182,460
Market Cap1.792B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-103.07
Earnings DateAug 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Did Viela Bio's (NASDAQ:VIE) Share Price Deserve to Gain 20%?
    Simply Wall St.

    Did Viela Bio's (NASDAQ:VIE) Share Price Deserve to Gain 20%?

    The last three months have been tough on Viela Bio, Inc. (NASDAQ:VIE) shareholders, who have seen the share price...

  • GlobeNewswire

    Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020

    GAITHERSBURG, Md., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced that four abstracts have been accepted for presentation, including a late-breaker, at the upcoming 8th Joint Congress of the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The congress will be held virtually on September 11-13, 2020 with an Encore event featuring late-breaker and COVID-19 presentations on September 26, 2020. Poster Presentations: Title: AQP4-IgG seronegative patients in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder (P0189) Date: Friday, September 11, 2020 Time: 8:00 AM EDTTitle: Serum neurofilament light chain levels (sNfL) correlate with attack-related disability in neuromyelitis optica (P0155) Date: Friday, September 11, 2020 Time: 8:00 AM EDTTitle: Quiescent MRI activity in NMOSD: results from the N-MOmentum randomized placebo- controlled trial (P0229) Date: Friday, September 11, 2020 Time: 8:00 AM EDTLate-Breaker Presentation: Title: Pharmacodynamic modeling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders (LB1239) Date: Saturday, September 26, 2020 Time: 8:00 AM EDTAbout Viela BioViela Bio, headquartered in Gaithersburg, Maryland, is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases. For more information, please visit www.vielabio.com.Source: Viela Bio Contacts:Investors: Solebury Trout Chad Rubin 646-378-2947 crubin@soleburytrout.com Media: Solebury Trout Amy Bonanno 914-450-0349 abonanno@soleburytrout.com

  • Viela Bio Inc (VIE) Q2 2020 Earnings Call Transcript
    Motley Fool

    Viela Bio Inc (VIE) Q2 2020 Earnings Call Transcript

    The press release reporting our financial results is available on the Investor and Media page of Veila's website at www.vielabio.com. Joining me on this call today are, Bing Yao, our chairman and chief executive officer, Jorn Drappa, our chief medical officer and head of R&D, and Bill Ragatz, vice president, head of the commercial.